ABPA AN OVERVIEW DIAGNOSIS AND CLASSIFICATION By DrAmit Kumar What is ABPA ABPA is an idiopathic inflammatory lung disease characterized by an allergic inflammatory response to the colonization of ID: 775062
Download Presentation The PPT/PDF document " ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS(ABPA) AN OVERVIEW DIAGNOSIS AND CLASSIFICATION
By Dr.Amit Kumar
Slide2What is ABPA?
ABPA is an idiopathic inflammatory lung disease characterized by an allergic inflammatory response to the colonization of
aspergillus
fumigatus
.
In another way
“
ABPA is an immunologic pulmonary disorder caused by hypersensitivity to the
aspergillus
fumigatus
.
“
It was first described in
1952 by Hinson
and
coworkers
and then again in 1967, when
Scadding
recognized an association of this disease with proximal
bronchiectasis
in areas previously affected by infiltrates
(predominantly in the upper lobes). The first adult case of ABPA in the United States was described in
1968
Slide3Aspergillus is an ubiquitous, thermotolerant mold. That reside in decaying organic matter.
What is Aspergillus
?
Slide4Slide5There are approximately 250 species of Aspergillus, but only a few are human pathogens. Depending on the host immunity and the organism virulence, the respiratory disease caused by aspergillus are aspergilloma, allergic aspergillus sinusitits, ABPA, hypersensitivity pneumonias, airway invasive aspergillosis, chronic necrotizing pulmonary aspergillosis and invasive aspergillosis.
The spectrum of disease is broad and can be severe and debilitating, requiring lung transplantation, however if recognized early and managed aggressively, ABPA is treatable can remit indefinitely and progressive lung damage can be avoided.
Slide6Epidemiology
There is no gender predilection and majority of the cases present in the third to fifth decade of life but may also present during childhood.
The prevalence of ABPA is about
1-2% in asthma patients
and
2-15% in cystic fibrosis patients
.
In the past two decades, there has been an increase in the number of cases of ABPA due to the heightened physician awareness and the wide spread availability of serologic assays.
In a recent meta analysis a prevalence of aspergillus hypersensitivity and ABPA in asthma of 28% and 12.9% respectively.
Slide7Pathogenesis of ABPA
Although the pathogenesis of ABPA is incompletely understood, it is believed to result from a complex immunological reaction to chronic airway colonization by aspergillus. Inhaled spores colonize the airway, proliferate and result in chronic antigenic stimulation of the airway, tissue injury and the clinical features of ABPA.
Slide8Slide9Slide10At the microscopic level ABPA is characterized by an
intense eosinophilic and mononuclear cell inflammatory response that leads to airway
injury
and bronchiectasis.
A role for
type I hypersensitivity
reactions is strongly suggested by the elevated serum levels of total and
Aspergillus-specific IgE.
Type III hypersensitivity
is suggested by the presence of
Aspergillus ,
precipitins and circulating immune complexes during disease exacerbations.
A
type IV cell-mediated immune
reaction may also be at work, based on the finding of dual (immediate and delayed) cutaneous reactions and in vitro lymphocyte transformation to
Aspergillus antigen stimulation
in some patients.
Slide11CLINICAL PRESENTATION
Common signs and symptoms
Low grade fever
Wheezing
Bronchial hyperactivity
Haemoptysis
Productive cough (often associated with brownish black mucus plugs)
Slide12Slide13PHYSICAL EXAMINATION
Can be normal
Other possible findings include :
Polyphonic wheezing
Clubbing (16%)
Coarse crackles (15%)
Sign and symptoms of pulmonary HTN and/or respiratory failure.
During exacerbations of ABPA, localized findings of consolidation and atelectasis can occur.
Slide14LABORATORY FINDINGSAspergillus Skin Test: The Aspergillus skin test is performed using an A fumigatus antigen. An immediate cutaneous hypersensitivity to A fumigatus antigens is a characteristic finding of ABPA and represents the presence A fumigatus specific IgE antibodies, whereas a type III skin reaction probably represents the immune complex hypersensitivity reaction, although its exact significance remains unclear.
Slide15Total Serum IgE Levels
Total Serum
IgE
Levels
:
The total
IgE
level is the most useful test for diagnosis and follow-up of ABPA. A normal serum
IgE
level excludes ABPA as the cause of the patient’s current symptoms. The only situation where
IgE
levels can be normal in active ABPA is when the patient is already on
glucocorticoid
therapy for any reason and investigation for
IgE
levels has been conducted. After treatment with
glucocorticoids
, the serum
IgE
levels decline, and a 35 to 50% decrease is taken as a criteria for remission. The serum
IgE
determination is also used for follow-up, and a doubling of the patient’s baseline
IgE
levels indicates relapse of ABPA.
Slide16Serum
IgE
and
IgG
Antibodies Specific to A fumigates
:
An elevated level of A
fumigatus
-specific antibodies measured by fluorescent enzyme immunoassay is considered the hallmark of ABPA. A cutoff value of
IgG
/
IgE
more than twice the pooled serum samples from patients with AH can greatly help in the differentiation of ABPA from other conditions
Slide17Radiologic Investigations:
A wide spectrum of radiographic appearances can occur in ABPA. The chest radiographic findings of ABPA include transient or fixed pulmonary opacities, tramline shadows, finger-in-glove opacities, and toothpaste shadows. Findings noted on high-resolution CT (HRCT) include central
bronchiectasis
,
mucoid
impaction, mosaic attenuation, presence of
centrilobular
nodules, and tree-in-bud opacities
Slide18Slide19Serum Precipitins Against A
fumigatus
:
They can also be present in other pulmonary disorders and thus represent supportive not diagnostic evidence for ABPA.
Peripheral
Eosinophilia
:
A blood absolute
eosinophil
count > 1,000 cells/
L is also a major criterion for the diagnosis of ABPA. A low
eosinophil
count does not exclude the diagnosis of ABPA.
Sputum Cultures for A
fumigatus
:
Culture of A
fumigatus
in the sputum is supportive but not diagnostic of ABPA.
Slide20Pulmonary Function Tests:
These tests help categorize the severity of the lung disease but have no diagnostic value in ABPA
Role of Specific
Aspergillus
Antigens:
The recombinant allergens Asp f1, Asp f2, Asp f3, Asp f4, and Asp f6 have been evaluated
for
their
diagnostic performance in serologic studies in asthmatic patients and in patients with CF Preliminary data suggest a promising role of these antigens in the diagnosis of ABPA. Further studies are required before they can be implemented in routine clinical practice.
Slide21Diagnosis and Diagnostic Criteria
Criteria Used for the Diagnosis of ABPA
Rosenberg-Patterson criteria
Major criteria (mnemonic
ARTEPICS
)
A = Asthma
R = Roentgenographic fleeting pulmonary opacities
T = Skin test positive for Aspergillus (type I reaction, immediate cutaneous hyperreactivity)
E = Eosinophilia
P = Precipitating antibodies (IgG) in serum
I = IgE in serum elevated (>1,000 IU/mL)
C = Central bronchiectasis
S = Serums A fumigatus-specific IgG and IgE (more than twice the value of pooled serum samples from patients with asthma who have Aspergillus hypersensitivity)
Slide22Presence of Aspergillus in sputumExpectoration of brownish black mucus plugsDelayed skin reaction to Aspergillus antigen (type III reaction)The presence of six of eight major criteria makes the diagnosis almost certain. The disease is further classified as ABPA-S or ABPA-CB on the absence or presence of central bronchiectasis, respectively
Minor criteria
Slide23Minimal ABPA-CB ( Central Bronchiectasis)AsthmaImmediate cutaneous hyperreactivity to Aspergillus antigensCentral bronchiectasisElevated IgERaised A fumigatus-specific IgG and IgEMinimal ABPA-S (Serum)AsthmaImmediate cutaneous hyperreactivity to Aspergillus antigensTransient pulmonary infiltrates on chest radiographElevated IgERaised A fumigatus-specific IgG and IgE
Minimal diagnostic criteria for ABPA
Slide24STAGING OF ABPA
:
ABPA has been classified into five stages, but a patient does not necessarily progress from one stage to the other sequentially.
Stage - I :
Acute phase
Acute asthma
symptoms,
fever
, weight
loss
.
Elevated serum IgE (
>1000 IU/ml)
Peripheral blood
eosinophilia
(may be absent in
patients
treated with oral
coricosteroids
)
Fleeting infiltrates on chest x-ray (may be absent in
patients
treated with oral
coricosteroids
)
Positive specific
IgE
,
IgG
, skin test reactivity, and
precipitins
to
A.
fumigatus
Responds to steroids/antifungal therapy
Slide25Stage – II :
Remission
Asymptomatic
Generally normal or significant resolution of radiologic opacities from the acute phase
Usually 35–50% decline in IgE levels by 6 wk to 3 mo; we give additional label of “complete remission” if the patient did not have any additional ABPA exacerbations over the next 3 mo after stopping steroid therapy
Slide26Stage III: Exacerbation/recurrenceRecurrence/worsenning of clinical symptomsRecurrent pulmonary infiltratesRising IgE levels
Disease is characterized by the development of new pulmonary infiltrates or by a
>100 percent increase in total IgE.
Elevation
of IgE may precede clinical or radiological worsening during this stage, and an isolated increase in severity of bronchospasm does not constitute an exacerbation. Although a
majority of disease exacerbations are associated with a concomitant increase in symptoms, exacerbations may occur in
the absence of any increase in symptoms.
Slide27Stage - IV :
Glucocorticoid-dependent ABPA
Symptomatic
Transient or fixed pulmonary opacities
Two groups can be identified: one in whom IgE levels do not rise but require steroids for asthma control (glucocorticoid dependent asthma); the other in whom steroids are required to continually suppress the disease activity (glucocorticoid dependent ABPA)
Slide28Stage - V :
End-stage (fibrotic) ABPA
Symptomatic, findings of fixed airway obstruction, severe pulmonary dysfunction, type II respiratory failure, cor pulmonale
Evidence of bronchiectasis, pulmonary fibrosis, pulmonary hypertension
Serum IgE levels and specific immunoglobulins do not become normal in most patients, and even these patients can have frequent exacerbations
Slide29Slide30Differential Diagnosis and Complication
The disorder needs to be differentiated from the following conditions:
Aspergillus hypersensitive bronchial asthma,
Pulmonary tuberculosis in endemic areas,
Community-acquired pneumonia (especially acute presentations),
and other inflammatory pulmonary disorders such as eosinophilic pneumonia,Bronchocentric Granulomatosis, and Churg-Strauss syndrome.
The complications of ABPA include recurrent asthma exacerbations and, if untreated, the development of bronchiectasis with subsequent pulmonary hypertension and respiratory failure. In fact, this is the reason why routine screening is recommended in bronchial asthma to prevent the complications just described.
Slide31Slide32Slide33ABPA IN SPECIAL SITUATIONS
ABPA Complicating CF:
The association of ABPA and CF was first reported in 1965. The occurrence of ABPA in CF is associated with deterioration of lung function, higher rates of microbial colonization, pneumothorax, massive hemoptysis, and poorer nutritional status.
Screening for ABPA in CF
1. Maintain a high level of suspicion for ABPA in patients with CF.
2. Determine the total serum IgE levels annually. If the total serum IgE levels is > 500 IU/mL, perform A fumigatus skin test or use an IgE antibody to A fumigatus. If results are positive, consider diagnosis on the basis of minimal criteria.
3. If the total serum IgE levels is 200–500 IU/mL, repeat the measurement if there is increased suspicion for ABPA and perform further diagnostic tests (immediate skin test reactivity to A fumigatus, IgE antibody to A fumigatus, A fumigatus precipitins, or serum IgG antibody to A fumigatus, and chest radiography).
Slide34ABPA Complicating Other Conditions:
Occasionally ABPA has been reported to complicate other lung diseases like idiopathic bronchiectasis, post-tubercular bronchiectasis, bronchiectasis secondary to Kartagener syndrome, COPD, and in patients with chronic granulomatous disease and hyper IgE syndrome.
Coexistence of ABPA and Aspergilloma:
The serologic findings of ABPA have also been reported in patients with aspergilloma and chronic necrotizing pulmonary aspergillosis.
ABPA without Bronchial Asthma:
ABPA may occasionaly develop in an individual without pre existing asthma.
Slide35Allergic Bronchopulmonary Mycosis:
Allergic bronchopulmonary mycosis is the occurrence of an ABPA-like syndrome due to non-A fumigatus fungal organisms.
ABPA and Allergic Aspergillus Sinusitis:
Allergic Aspergillus sinusitis (AAS) is a clinical entity in which mucoid impaction akin to that of ABPA occurs in the paranasal sinuses.
Slide36PROGNOSIS:
With appropriate treatment long-term control of ABPA is feasible, and durable remissions are common.
Treatment of
stage I disease with corticosteroids
typically results in decreased sputum production, improved control of bronchospasm,
>
35 percent reduction in total IgE within 8weeks, clearing of precipitating antibodies, and resolution of radiographic infiltrates. IgE levels typically do not completely normalize but rather decrease by approximately one-half of peak levels seen in the acute stage.
Progression of stage IV disease to pulmonary fibrosis can be prevented if patients are maintained on
low-dose steroids
, and most patients with stage V disease have a stable course over several years. Persons with an FEV1 persistently
<0.8 L have a worse prognosis.
In addition
to severe airflow obstruction and pulmonary fibrosis, longterm complications of ABPA occasionally include the development of an aspergilloma , chronic or recurrent lobar atelectasis, allergic
Aspergillus sinusitis, or Aspergillus
tissue invasion and semi-invasive
Aspergillosis.
Transplantation
has been undertaken successfully among patients with ABPA, however, post-transplant recurrence ofABPA has beenreported.
Slide37CONCLUSIONS
A high index of suspicion for ABPA should be maintained while managing any patient with bronchial asthma whatever the severity or the level of control. Host immunologic responses are central to the pathogenesis, and they are the primary determinants of the clinical, biologic, pathologic, and radiologic features of this disorder. ABPA may precede the clinical recognition of the disorder for many years or even decades, and it is often misdiagnosed as a variety of pulmonary diseases. Because a patient with ABPA can be minimally symptomatic or asymptomatic, all patients with bronchial asthma should be routinely screened with an
Aspergillus
skin test.
In
patients with
Aspergillus
hypersensitivity, further immunologic studies are warranted to diagnose ABPA before the development of
bronchiectasis
because
bronchiectasis
is a poor prognostic marker in the natural history of this disease.
Slide38